

SUPPLEMENTAL MATERIALS

Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions

Meera Varshneya,* Itziar Irurzun-Arana,* Chiara Campana, Rafael Dariolli, Amy Gutierrez, Taylor K. Pullinger, Eric A. Sobie

*Equal contributions

Correspondence: eric.sobie@mssm.edu

Supplemental material for this manuscript consists of links to model code and 3 supplemental tables that provide additional methodological information.

Availability of model code

Mathematical models that were used to generate this manuscript's results were implemented in MATLAB (Figures 1, 3, and 4) or R (Figure 2). These source files have been placed at the first author's github repository and are freely available for download:

https://github.com/meeravarshneya1234/COVID19Drugs_ArrhythmiaRisk

Table S1: Drug Channel Block Characteristics

Drug	IC₅₀ I_{Kr} (nM)	IC₅₀ I_{CaL} (nM)	IC₅₀ I_{Na} (nM)	IC₅₀ I_{NaL} (nM)	IC₅₀ I_{Ks} (nM)	IC₅₀ I_{K1} (nM)	IC₅₀ I_{to} (nM)
Azithromycin	70796	-	-	189128	470131	-	88764
Chloroquine	6889	-	-	-	-	10595	-
Lopinavir	5170	15601	-	-	-	-	-
Ritonavir	5157	8228	-	7175	-	-	-

Drug	EFTPC (nM)	h I_{Kr}	h I_{CaL}	h I_{Na}	h I_{NaL}	H I_{Ks}	h I_{K1}	h I_{to}
Azithromycin	1937	0.5	-	-	1.9	1.4	-	0.5
Chloroquine	249.5	0.6	-	-	-	-	0.8	-
Lopinavir	703.7	1.2	1	-	-	-	-	-
Ritonavir	436.9	1	1.3	-	0.7	-	-	-

IC₅₀ values and Hill coefficients taken from a study that measured block of 7 cardiac ion channels by 30 drugs under standardized conditions.¹

Table S2: Phenotypic group parameterization

The model parameters in Table S1 were used to describe the healthy male phenotype while the remaining three groups were scaled based on published data. The healthy female scaling factors were taken from Yang et al.,² while the heart failure male were taken from Gomez et. al.³ The heart failure female group was formed by multiplying the healthy female and heart failure male groups.

Parameter	Healthy Male	Healthy Female	Heart Failure Male	Heart Failure Female
$\bar{G}_{Na,fast}$	1	1	1	1
$\bar{G}_{Na,late}$	1	1	1.8	1.8
\bar{G}_{to}	1	0.64	0.4	.256
\bar{G}_{Kr}	1	0.79	1	0.79
\bar{G}_{Ks}	1	0.83	1	0.83
\bar{G}_{K1}	1	0.86	0.68	0.5848
\bar{G}_{NaCa}	1	1	1.75	1.75
\bar{G}_{Kb}	1	1	1	1
P_{Ca}	1	1	1	1
\bar{I}_{NaK}	1	0.79	0.7	0.5530
P_{Nab}	1	1	1	1
P_{Cab}	1	1	1	1
\bar{G}_{pCa}	1	1	1	1
$SERCA_{total}$	1	1.15	0.5	0.5750
RyR_{total}	1	1	1	1
$Trans_{total}$	1	1	1	1
$Leak_{total}$	1	1	1.3	1.3
K_{CaMK}	1	1	1.5	1.5

Model Parameters**Table S3: Channel Conductance Parameters varied in O'Hara Model⁴**

Parameter	Definition	Baseline value ¹
$\bar{G}_{Na,fast}$	Maximal Na ⁺ conductance	75 mS/ μ F
$\bar{G}_{Na,late}$	Maximal late Na ⁺ conductance	0.0075 mS/ μ F
\bar{G}_{to}	Maximal transient outward K ⁺ conductance	0.02 mS/ μ F
\bar{G}_{Kr}	Rapid delayed rectifier K ⁺ conductance scaling factor ¹	0.046 mS/ μ F
\bar{G}_{Ks}	Slow delayed rectifier K ⁺ conductance scaling factor ²	0.0034 mS/ μ F
\bar{G}_{K1}	Inward rectifier K ⁺ conductance scaling factor ¹	0.1908 mS/ μ F
\bar{G}_{NaCa}	Maximal Na ⁺ -Ca ²⁺ exchange current	0.0008 μ A/ μ F
\bar{G}_{Kb}	Maximal conductance of background K ⁺	0.003 mS/ μ F
P_{Ca}	L-type Ca ²⁺ current permeability	0.0001 cm/s
\bar{I}_{NaK}	Scales the Na ⁺ -K ⁺ ATPase current	30
P_{Nab}	Background Na ⁺ current permeability	3.75e-10 cm/s
P_{Cab}	Background Ca ²⁺ current permeability	2.5e-8 cm/s
\bar{G}_{pCa}	Maximal sarcolemmal Ca ²⁺ pump current	0.0005 mS/ μ F
$SERCA_{total}$	SR Ca ²⁺ release scaling factor ⁴	1
RyR_{total}	SR Ca ²⁺ uptake (SERCA) scaling factor ⁴	1
$Trans_{total}$	NSR to JSR Ca ²⁺ translocation ⁴	1
$Leak_{total}$	Ca ²⁺ Leak from the NSR ⁴	1

Notes

¹The scaling factors for I_{K1} and I_{Kr} are not formally maximal conductance, since each is multiplied by $\sqrt{K_o}/5.4$ and can therefore be greater than this value. Changing this factor scales the current at all values of extracellular [K⁺] while maintaining the dependence on this variable.

²The scaling factor for I_{Ks} is multiplied by a function of intracellular [Ca²⁺]. This value is therefore not precisely the current's maximal conductance.

³ \bar{I}_{NaK} was not labeled in the original paper and have been given these names to keep to terminology consistent.

⁴Parameters controlling the magnitude of these channels are an introduced unitless multiplier with baseline value equals to 1.00.

REFERENCES

1. Crumb WJ, Jr., Vicente J, Johannesen L, Strauss DG. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. *J Pharmacol Toxicol Methods* **81** 251-262. (2016)
2. Yang PC, *et al.* A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias. *J Physiol* **595** 4695-4723. (2017)
3. Gomez JF, Cardona K, Romero L, Ferrero JM, Jr., Trenor B. Electrophysiological and structural remodeling in heart failure modulate arrhythmogenesis. 1D simulation study. *PLoS One* **9** e106602. (2014)
4. O'Hara T, Virag L, Varro A, Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. *PLoS Comput Biol* **7** e1002061. (2011)